FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168543180> ?p ?o ?g. }

• W2168543180 endingPage "223" @default.
• W2168543180 startingPage "221" @default.
• W2168543180 abstract "In this edition of Leukemia and Lymphoma , Greenberg and colleagues report the results of their eff ort to fi nd a signal of activity of the thrombopoeitin (TPO)-mimetic agent romiplostim when combined with decitabine for the treatment of myelodysplasia (MDS) [1]. Th e clinical and methodological questions raised by this study are important, and speak to both the potential role of the TPO-receptor agonists as supportive care agents in myelodysplasia, and the scientifi c and methodological pitfalls of clinical development in this particularly heterogeneous target population. As the authors acknowledge, the sample size of this trial is insuffi cient to allow any statistically sound conclusions about the effi cacy of the TPO-mimetic. Nevertheless, the observations regarding tolerability and a signal of drug activity are of interest. Th e context of these trials is the historical concern that activation of c-mpl, the target of TPO, may promote acute myeloid leukemia (AML) blast survival [2 – 4] and increase the rate of progression of MDS to AML [5]. Transient elevations of the marrow blast count to greater than 20% were noted in four of 41 patients in the phase II study of romiplostim monotherapy in patients with lower risk MDS, all falling to 10% after withdrawal of the drug [6]. Another two of 41 patients progressed to AML, probably consistent with the natural history of the disease. One hypothesis for this eff ect is that activation of the mpl receptor has a stem-cell mobilizingeff ect, a hypothesis supported by clinical observations from trials of recombinant TPO [7]. Amgen have recently issued a formal notice of a risk of progression of International Prognostic System Score (IPSS) low- and intermediate-1 MDS to AML [8] in patients receiving romiplostim, a consequence of early data from the placebo-controlled randomized trial of the drug as monotherapy in patients with lower risk MDS [9]. Meanwhile Glaxo-Smith-Kline (GSK) continues its development of the small molecule mpl agonist eltrombopag in this fi eld, including studies in patients with higher risk MDS than those selected for the romiplostim studies, with no sugges" @default.
• W2168543180 created "2016-06-24" @default.
• W2168543180 creator A5027391845 @default.
• W2168543180 date "2012-11-07" @default.
• W2168543180 modified "2023-10-05" @default.
• W2168543180 title "Supportive care for thrombocytopenia in patients receiving treatment for myelodysplasia: a challenge for the future" @default.
• W2168543180 cites W1967615994 @default.
• W2168543180 cites W1969729439 @default.
• W2168543180 cites W1980697643 @default.
• W2168543180 cites W1991772482 @default.
• W2168543180 cites W1997524491 @default.
• W2168543180 cites W1998560266 @default.
• W2168543180 cites W2002311977 @default.
• W2168543180 cites W2028751390 @default.
• W2168543180 cites W2032015430 @default.
• W2168543180 cites W2036068780 @default.
• W2168543180 cites W2041481720 @default.
• W2168543180 cites W2042932387 @default.
• W2168543180 cites W2049217001 @default.
• W2168543180 cites W2082310541 @default.
• W2168543180 cites W2103336749 @default.
• W2168543180 cites W2118771330 @default.
• W2168543180 cites W2125438418 @default.
• W2168543180 cites W2134292391 @default.
• W2168543180 cites W2145859825 @default.
• W2168543180 cites W2167203608 @default.
• W2168543180 cites W2313856222 @default.
• W2168543180 cites W2583784450 @default.
• W2168543180 cites W4211167997 @default.
• W2168543180 doi "https://doi.org/10.3109/10428194.2012.738817" @default.
• W2168543180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23057595" @default.
• W2168543180 hasPublicationYear "2012" @default.
• W2168543180 type Work @default.
• W2168543180 sameAs 2168543180 @default.
• W2168543180 citedByCount "0" @default.
• W2168543180 crossrefType "journal-article" @default.
• W2168543180 hasAuthorship W2168543180A5027391845 @default.
• W2168543180 hasBestOaLocation W21685431801 @default.
• W2168543180 hasConcept C126322002 @default.
• W2168543180 hasConcept C177713679 @default.
• W2168543180 hasConcept C2780007613 @default.
• W2168543180 hasConcept C2780817109 @default.
• W2168543180 hasConcept C71924100 @default.
• W2168543180 hasConceptScore W2168543180C126322002 @default.
• W2168543180 hasConceptScore W2168543180C177713679 @default.
• W2168543180 hasConceptScore W2168543180C2780007613 @default.
• W2168543180 hasConceptScore W2168543180C2780817109 @default.
• W2168543180 hasConceptScore W2168543180C71924100 @default.
• W2168543180 hasIssue "2" @default.
• W2168543180 hasLocation W21685431801 @default.
• W2168543180 hasLocation W21685431802 @default.
• W2168543180 hasOpenAccess W2168543180 @default.
• W2168543180 hasPrimaryLocation W21685431801 @default.
• W2168543180 hasRelatedWork W1506200166 @default.
• W2168543180 hasRelatedWork W1995515455 @default.
• W2168543180 hasRelatedWork W2048182022 @default.
• W2168543180 hasRelatedWork W2080531066 @default.
• W2168543180 hasRelatedWork W2588524359 @default.
• W2168543180 hasRelatedWork W2748952813 @default.
• W2168543180 hasRelatedWork W2899084033 @default.
• W2168543180 hasRelatedWork W3031052312 @default.
• W2168543180 hasRelatedWork W3032375762 @default.
• W2168543180 hasRelatedWork W3108674512 @default.
• W2168543180 hasVolume "54" @default.
• W2168543180 isParatext "false" @default.
• W2168543180 isRetracted "false" @default.
• W2168543180 magId "2168543180" @default.
• W2168543180 workType "article" @default.